The Comparative Safety and Effectiveness of Warfarin and Dabigatran Prescribed in the Non-valvular Atrial Fibrillation Population With Humana Healthcare Coverage
| Status: | Completed |
|---|---|
| Conditions: | Atrial Fibrillation |
| Therapuetic Areas: | Cardiology / Vascular Diseases |
| Healthy: | No |
| Age Range: | 18 - 89 |
| Updated: | 6/9/2017 |
| Start Date: | October 28, 2014 |
| End Date: | March 15, 2016 |
The Comparative Safety and Effectiveness of Warfarin and Dabigatran Utilized in the Humana Non-Valvular Atrial Fibrillation (NVAF) Patient Population-A Retrospective Database Analysis
This study is an opportunity for Boehringer Ingelheim to collaborate with Humana to conduct
comparative safety and effectiveness studies of dabigatran and warfarin using real world
data from Humana's health plan operations.
comparative safety and effectiveness studies of dabigatran and warfarin using real world
data from Humana's health plan operations.
Study Design:
Inclusion criteria:
- Patient must have at least one inpatient, one physician office visit, or one
emergency room visit with a diagnosis of AF on the index date or during the pre-index
period.
- Patients must be continuously enrolled in a health plan during the pre-index period
- Patient must have a prescription for dabigatran or warfarin
- Patient must be treatment naive from all oral anticoagulant (OAC) use prior to first
OAC prescription
- Aged 18-89 years on the index date. The index date is defined as the date of the
first OAC prescription
Exclusion criteria:
- Diagnosis of hyperthyroidism during the pre-index period,
- Having claims for any of the following within 3 months prior to the first diagnosis
of AF: cardiac surgery, pericarditis, myocarditis, pulmonary embolism.
- Any patients with at least one medical claim for valvular heart disease.
We found this trial at
1
site
Click here to add this to my saved trials
